UK’s withdrawal from the EU

EMA publishes first thoughts on implications and mitigating actions.

The Management Board endorsed the mandates of two working groups, one focusing on human medicines and one on veterinary medicines, that will explore options for a robust allocation of the workload across the European medicines regulatory network and ways to streamline work and further increase capacity in the network.

The Board endorsed a business continuity plan on the principles and the methodology that will help EMA prioritize its activities to make available the necessary resources to prepare for ‘Brexit’ and cope with a potentially significant staff loss.

EMA and the European Commission are providing guidance to help pharmaceutical companies responsible for both human and veterinary medicines prepare for the UK's withdrawal from the EU.

Read more online
Copyright Widler & Schiemann AG 2015. All Rights Reserved. /